Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Curr Opin Rheumatol. 2018 Nov;30(6):548–553. doi: 10.1097/BOR.0000000000000550

Table 1.

Newly described clinical characteristics associated with both well-defined and novel autoantibodies found in patients with systemic sclerosis. ILD: interstitial lung disease; PAH: pulmonary arterial hypertension, GI-gastrointestinal.

Antibodies in Scleroderma Antibody
abbreviation		 Salient Features and Clinical Associations
RNA polymerase III RNA pol III Malignancy (notably breast and lung cancer)2, 6–7
RNA Binding Region Containing 3 RNPC3 Malignancy, ILD, GI dysmotility, myopathy9–10
Ribonuclease P protein subunit 25 Rpp25 Antigen target of anti-Th/To immune response13
Eukaryotic initiation factor 2B eIF2B Diffuse cutaneous disease, I LD14
RuvBL1 & RuvsBL2 RuvBL1/2 Diffuse cutaneous disease, inflammatory myositis overlap15, 17
Bicaudal D homolog 2 BICD2 Inflammatory myositis, ILD18
Interferon-inducible protein 16 IFI16 Digital ischemia21–23
Angiotensin II type I receptor AT1R Vascular disease (digital ischemia, PAH)27–28
Endothelin-1 type A receptor ETAR Vascular disease (digital ischemia, PAH)27–28
Muscarinic-3 receptor M3R GI dysmotility30–31
Platelet-derived growth factor receptor PDGFR Controversial, possibly profibrotic32,33